Skip to main content
SpringerLink
Log in

Dupilumab Facial Redness/Dupilumab Facial Dermatitis: A Guide for Clinicians

  • Therapy in Practice
  • Published:
American Journal of Clinical Dermatology Aims and scope Submit manuscript

Abstract

Dupilumab facial redness (DFR), or the development of an eczematous rash of the face and neck with dupilumab use, has been observed in recent case reports. It is estimated to impact between 4 and 43.8% of dupilumab users, including children and adults. Aside from reviewing the pathogenesis and clinical presentation, we present potential diagnostic steps (such as skin scraping, serologies, biopsy, and patch testing) and management options for DFR ranging from allergen avoidance to dupilumab interruption. It is hoped that this article will serve as a means for clinicians to familiarize themselves with DFR regarding the differential diagnosis, diagnostic tools, and treatment options associated with this phenomenon.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Deleanu D, Nedelea I. Biological therapies for atopic dermatitis: an update (review). Experimental and Therapeutic Medicine [Internet]. Spandidos Publications; 2019 [cited 2021 Apr 17];17:1061–7. Available from: https://pubmed-ncbi-nlm-nih-gov.ezproxy.lib.uconn.edu/30679974/.

  2. Gooderham MJ, Hong HC ho, Eshtiaghi P, Papp KA. Dupilumab: a review of its use in the treatment of atopic dermatitis. Journal of the American Academy of Dermatology [Internet]. Mosby Inc.; 2018 [cited 2021 Apr 17];78:S28–36. Available from: https://pubmed-ncbi-nlm-nih-gov.ezproxy.lib.uconn.edu/29471919/.

  3. Zhang X, Yang Y, Grimstein M, Fan J, Grillo JA, Huang SM, et al. Application of PBPK modeling and simulation for regulatory decision making and its impact on US prescribing information: an update on the 2018–2019 Submissions to the US FDA’s Office of Clinical Pharmacology. Journal of Clinical Pharmacology [Internet]. Blackwell Publishing Inc.; 2020 [cited 2021 Apr 17];60:S160–78. Available from: https://pubmed-ncbi-nlm-nih-gov.ezproxy.lib.uconn.edu/33205429/.

  4. Deleuran M, Thaçi D, Beck LA, de Bruin-Weller M, Blauvelt A, Forman S, et al. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. Journal of the American Academy of Dermatology [Internet]. Mosby Inc.; 2020 [cited 2021 Apr 17];82:377–88. Available from: https://pubmed-ncbi-nlm-nih-gov.ezproxy.lib.uconn.edu/31374300/.

  5. Worm M, Simpson EL, Thaçi D, Bissonnette R, Lacour JP, Beissert S, et al. Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis: a randomized clinical trial. JAMA Dermatology [Internet]. American Medical Association; 2020 [cited 2021 Apr 17];156:131–43. Available from: https://pubmed-ncbi-nlm-nih-gov.ezproxy.lib.uconn.edu/31876900/.

  6. Dalia Y, Johnson SM. Case report: first reported case of facial rash after dupilumab therapy [Internet]. Practical Dermatology. Bryn Mawr Communications; 2018 [cited 2021 Apr 17]. p. 25–6. Available from: https://practicaldermatology.com/articles/2018-apr/case-report-first-reported-case-of-facial-rash-after-dupilumab-therapy-call-for-abstracts.

  7. Albader SS, Alharbi AA, Alenezi RF, Alsaif FM. Dupilumab side effect in a patient with atopic dermatitis: a case report study. Biologics: Targets and Therapy [Internet]. Dove Medical Press Ltd.; 2019 [cited 2021 Apr 17];13:79–82. Available from: https://pubmed-ncbi-nlm-nih-gov.ezproxy.lib.uconn.edu/31190731/.

  8. de Beer FSA, Bakker DS, Haeck I, Ariens L, van der Schaft J, van Dijk MR, et al. Dupilumab facial redness: positive effect of itraconazole. JAAD Case Reports [Internet]. Elsevier Inc; 2019 [cited 2021 Apr 17];5:888–91. Available from: https://pubmed-ncbi-nlm-nih-gov.ezproxy.lib.uconn.edu/31681828/.

  9. de Wijs LEM, Nguyen NT, Kunkeler ACM, Nijsten T, Damman J, Hijnen DJ. Clinical and histopathological characterization of paradoxical head and neck erythema in patients with atopic dermatitis treated with dupilumab: a case series. British Journal of Dermatology [Internet]. Blackwell Publishing Ltd; 2020 [cited 2021 Apr 17];183:745–9. Available from: https://pubmed-ncbi-nlm-nih-gov.ezproxy.lib.uconn.edu/31749159/.

  10. Derrick KM, Glick SA. Red in the face: Dupilumab facial dermatitis in a 12 year old boy [poster]. Department of Dermatology, SUNY Downstate and Maimonides Medical Center.

  11. Jang DH, Lee JI, Bae JY, Jung HJ, Park MY, Ahn J. Facial erythema after the treatment of dupilumab in SLE patient. Allergy, Asthma and Clinical Immunology [Internet]. BioMed Central; 2020 [cited 2021 Apr 17];16. Available from: https://pubmed-ncbi-nlm-nih-gov.ezproxy.lib.uconn.edu/32944024/.

  12. Okiyama N, Nakamura Y, Ishitsuka Y, Inoue S, Kubota N, Saito A, et al. Successful topical treatment with ketoconazole for facial rashes refractory to dupilumab in patients with atopic dermatitis: case reports [Internet]. Journal of the European Academy of Dermatology and Venereology. Blackwell Publishing Ltd; 2020 [cited 2021 Apr 17]. p. e474–6. Available from: https://pubmed-ncbi-nlm-nih-gov.ezproxy.lib.uconn.edu/32215964/.

  13. Suresh R, Murase JE. The role of expanded series patch testing in identifying causality of residual facial dermatitis following initiation of dupilumab therapy. JAAD Case Reports [Internet]. Elsevier Inc; 2018 [cited 2021 Apr 17];4:899–904. Available from: https://pubmed-ncbi-nlm-nih-gov.ezproxy.lib.uconn.edu/30306123/.

  14. Waldman RA, DeWane ME, Sloan B, Grant-Kels JM. Characterizing dupilumab facial redness: a multi-institution retrospective medical record review. Journal of the American Academy of Dermatology [Internet]. Mosby Inc.; 2020 [cited 2021 Apr 17];82:230–2. Available from: https://pubmed-ncbi-nlm-nih-gov.ezproxy.lib.uconn.edu/31228530/.

  15. Muzumdar S, Zubkov M, Waldman R, DeWane ME, Wu R, Grant-Kels JM. Characterizing dupilumab facial redness in children and adolescents: a single-institution retrospective chart review. Journal of the American Academy of Dermatology [Internet]. Mosby Inc.; 2020 [cited 2021 Apr 17];83:1520–1. Available from: https://pubmed-ncbi-nlm-nih-gov.ezproxy.lib.uconn.edu/32622143/.

  16. Hendricks AJ, Shi VY. Learning about dupilumab-associated conjunctivitis [Internet]. JAMA Dermatology. American Medical Association; 2019 [cited 2021 Apr 17]. p. 754. Available from: https://pubmed-ncbi-nlm-nih-gov.ezproxy.lib.uconn.edu/30994889/.

  17. Bohner A, Topham C, Strunck J, Haynes D, Brazil M, Clements J, et al. Dupilumab-associated ocular surface disease: clinical characteristics, treatment, and follow-up. Cornea [Internet]. Ovid Technologies (Wolters Kluwer Health); 2021 [cited 2021 Apr 17];40:584–9. Available from: https://journals.lww.com/https://doi.org/10.1097/ICO.0000000000002461.

  18. Narla S, Silverberg JI, Simpson EL. Management of inadequate response and adverse effects to dupilumab in atopic dermatitis. Journal of the American Academy of Dermatology [Internet]. J Am Acad Dermatol; 2021 [cited 2021 Jul 30]; Available from: https://pubmed-ncbi-nlm-nih-gov.ezproxy.lib.uconn.edu/34126094/.

  19. Zhu GA, Chen JK, Chiou A, Ko J, Honari G. Assessment of the development of new regional dermatoses in patients treated for atopic dermatitis with dupilumab [Internet]. JAMA Dermatology. American Medical Association; 2019 [cited 2021 Apr 17]. p. 850–2. Available from: https://pubmed-ncbi-nlm-nih-gov.ezproxy.lib.uconn.edu/31042259/.

  20. Seok SH, An JH, Shin JU, Lee HJ, Kim DH, Yoon MS, et al. Facial redness in atopic dermatitis patients treated with dupilumab: a case series [Internet]. Allergy, Asthma and Immunology Research. Korean Academy of Asthma, Allergy and Clinical Immunology; 2020 [cited 2021 Apr 17]. p. 1063–5. Available from: https://pubmed-ncbi-nlm-nih-gov.ezproxy.lib.uconn.edu/32935496/.

  21. Adalsteinsson JA, Kaushik S, Muzumdar S, Guttman E, Ungar J. An update on the microbiology, immunology and genetics of seborrheic dermatitis [Internet]. Experimental Dermatology. Blackwell Publishing Ltd; 2020 [cited 2021 Apr 17]. p. 481–9. Available from: https://pubmed-ncbi-nlm-nih-gov.ezproxy.lib.uconn.edu/32125725/.

  22. Jo CE, Finstad A, Georgakopoulos JR, Piguet V, Yeung J, Drucker AM. Facial and neck erythema associated with dupilumab treatment: a systematic review. Journal of the American Academy of Dermatology [Internet]. J Am Acad Dermatol; 2021 [cited 2021 Jul 30];84:1339–47. Available from: https://pubmed-ncbi-nlm-nih-gov.ezproxy.lib.uconn.edu/33428978/.

  23. Kim GK. Seborrheic dermatitis and malassezia species: how are they related? The Journal of clinical and aesthetic dermatology [Internet]. Matrix Medical Communications; 2009 [cited 2021 Apr 17];2:14–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20725575.

  24. Owen JL, Vakharia PP, Silverberg JI. The role and diagnosis of allergic contact dermatitis in patients with atopic dermatitis. American Journal of Clinical Dermatology [Internet]. Springer International Publishing; 2018 [cited 2021 Apr 17];19:293–302. Available from: https://pubmed-ncbi-nlm-nih-gov.ezproxy.lib.uconn.edu/29305764/.

  25. Kim JH, Chun YS, Kim JC. Clinical and immunological responses in ocular demodecosis. Journal of Korean Medical Science [Internet]. J Korean Med Sci; 2011 [cited 2021 Apr 17];26:1231–7. Available from: https://pubmed-ncbi-nlm-nih-gov.ezproxy.lib.uconn.edu/21935281/.

  26. Buhl T, Sulk M, Nowak P, Buddenkotte J, McDonald I, Aubert J, et al. Molecular and morphological characterization of inflammatory infiltrate in rosacea reveals activation of Th1/Th17 pathways. Journal of Investigative Dermatology [Internet]. Nature Publishing Group; 2015 [cited 2021 Apr 17];135:2198–208. Available from: https://pubmed-ncbi-nlm-nih-gov.ezproxy.lib.uconn.edu/25848978/.

  27. Heibel HD, Hendricks AJ, Foshee JP, Shi VY. Rosacea associated with dupilumab therapy. Journal of Dermatological Treatment [Internet]. Taylor and Francis Ltd.; 2021 [cited 2021 Apr 17];32:114–6. Available from: https://pubmed-ncbi-nlm-nih-gov.ezproxy.lib.uconn.edu/31132923/.

  28. Jaros J, Hendricks AJ, Shi VY, Lio PA. A practical approach to recalcitrant face and neck dermatitis in atopic dermatitis [Internet]. Dermatitis. Lippincott Williams and Wilkins; 2020 [cited 2021 Apr 17]. p. 169–77. Available from: https://pubmed-ncbi-nlm-nih-gov.ezproxy.lib.uconn.edu/32355092/.

  29. Soria A, Du-Thanh A, Seneschal J, Jachiet M, Staumont-Sallé D, Barbarot S. Development or exacerbation of head and neck dermatitis in patients treated for atopic dermatitis with dupilumab [Internet]. JAMA Dermatology. American Medical Association; 2019 [cited 2021 Apr 17]. p. 1312–5. Available from: https://pubmed-ncbi-nlm-nih-gov.ezproxy.lib.uconn.edu/31483439/.

  30. Ashbaugh AG, Murase EM, Raffi J, Botto N, Murase JE. Characterization of residual facial dermatitis on dupilumab: a retrospective chart review to delineate the potential role of expanded series patch testing (in press). Dermatitis. 2021.

  31. Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. New England Journal of Medicine [Internet]. New England Journal of Medicine (NEJM/MMS); 2016 [cited 2021 Apr 17];375:2335–48. Available from: https://pubmed.ncbi.nlm.nih.gov/27690741/.

  32. Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. The Lancet [Internet]. Lancet Publishing Group; 2017 [cited 2021 Apr 17];389:2287–303. Available from: https://pubmed.ncbi.nlm.nih.gov/28478972/.

  33. de Bruin-Weller M, Thaçi D, Smith CH, Reich K, Cork MJ, Radin A, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). British Journal of Dermatology [Internet]. Blackwell Publishing Ltd; 2018 [cited 2021 Apr 17];178:1083–101. Available from: https://pubmed.ncbi.nlm.nih.gov/29193016/.

  34. Nahum Y, Mimouni M, Livny E, Bahar I, Hodak E, Leshem YA. Dupilumab-induced ocular surface disease (DIOSD) in patients with atopic dermatitis: clinical presentation, risk factors for development and outcomes of treatment with tacrolimus ointment. British Journal of Ophthalmology [Internet]. BMJ Publishing Group; 2020 [cited 2021 Apr 17];104:776–9. Available from: https://pubmed.ncbi.nlm.nih.gov/31554632/.

  35. Raffi J, Suresh R, Fishman H, Botto N, Murase JE. Investigating the role of allergic contact dermatitis in residual ocular surface disease on dupilumab (ROSDD). International journal of women’s dermatology [Internet]. Int J Womens Dermatol; 2019 [cited 2021 Oct 2];5:308–13. Available from: https://pubmed.ncbi.nlm.nih.gov/31909149/.

  36. Chen JK, Jacob SE, Nedorost ST, Hanifin JM, Simpson EL, Boguniewicz M, et al. A pragmatic approach to patch testing atopic dermatitis patients: clinical recommendations based on expert consensus opinion [Internet]. Dermatitis. Lippincott Williams and Wilkins; 2016 [cited 2021 Apr 17]. p. 186–92. Available from: https://pubmed.ncbi.nlm.nih.gov/27427820/.

  37. Zhu TH, Suresh R, Warshaw E, Scheinman P, Mowad C, Botto N, et al. The medical necessity of comprehensive patch testing [Internet]. Dermatitis. Lippincott Williams and Wilkins; 2018 [cited 2021 Apr 17]. p. 107–11. Available from: https://pubmed.ncbi.nlm.nih.gov/29613858/.

  38. Raffi J, Suresh R, Botto N, Murase JE. The impact of dupilumab on patch testing and the prevalence of comorbid allergic contact dermatitis in recalcitrant atopic dermatitis: a retrospective chart review. Journal of the American Academy of Dermatology [Internet]. Mosby Inc.; 2020 [cited 2021 Apr 17];82:132–8. Available from: https://pubmed.ncbi.nlm.nih.gov/31562940/.

  39. Gao DX, Song S, Kahn JS, Cohen SR, Fiumara K, Dumont N, et al. Treatment of patients experiencing dupilumab facial redness with itraconazole and fluconazole: a single-institutional, retrospective medical record review. Journal of the American Academy of Dermatology [Internet]. J Am Acad Dermatol; 2021 [cited 2021 Jul 30]; Available from: https://pubmed-ncbi-nlm-nih-gov.ezproxy.lib.uconn.edu/33775718/.

Download references

Author information

Authors and Affiliations

  1. University of Connecticut School of Medicine, Farmington, CT, USA

    Sonal Muzumdar

  2. University of Connecticut Department of Dermatology, 21 South Road, Farmington, CT, 06032, USA

    Lauren Skudalski & Reid A. Waldman

  3. Geisinger Commonwealth School of Medicine, Scranton, PA, USA

    Lauren Skudalski

  4. Frank H. Netter MD School of Medicine, North Haven, CT, USA

    Kelley Sharp

Authors
  1. Sonal Muzumdar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lauren Skudalski
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kelley Sharp
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Reid A. Waldman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Reid A. Waldman.

Ethics declarations

Funding

None.

Conflict of interest

None.

Ethics/IRB approval

Not applicable.

Consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and material

Not applicable.

Code availability

Not applicable.

Author contributions

SM performed the literature search, main drafter of the original submission. LS performed additional search of the literature, contributed to the original draft, critically revised the work. KS contributed to the original draft, critically revised the work. RW contributed to the original draft, critically revised the work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Muzumdar, S., Skudalski, L., Sharp, K. et al. Dupilumab Facial Redness/Dupilumab Facial Dermatitis: A Guide for Clinicians. Am J Clin Dermatol 23, 61–67 (2022). https://doi.org/10.1007/s40257-021-00646-z

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40257-021-00646-z

Search

Navigation